Meeting
2014 ASCO Annual Meeting
The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma.
Authors
Christiana Bitas
Memorial Sloan Kettering Cancer Center, New York, NY
Christiana Bitas , Alexander Noor Shoushtari , Mark J. Bluth , Gauri Bhuchar , Robert Harrison Hester , Jacqueline Romero , Laura Fitzpatrick , Robert A Lefkowitz , Katherine Panageas , Gary K. Schwartz , Margaret K. Callahan , Michael Andrew Postow , Jedd D. Wolchok , Paul B. Chapman , Richard D. Carvajal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9073)
DOI
10.1200/jco.2014.32.15_suppl.9073
Abstract #
9073
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
First Author: Douglas Buckner Johnson
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2022 ASCO Annual Meeting
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Lisa A. Kottschade
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton